Lucid Diagnostics Inc. (LUCD)

Lucid Diagnostics' stock price has experienced fluctuations in the past six months, trading between $0.95 and $1.80 over the past year, with a 22.58% decline between March 25, 2025, and March 24, 2026. Recent events include the Q4 2025 earnings report, where the stock declined by 3.4% despite exceeding revenue targets and processing 3,664 EsoGuard tests. The company was awarded a contract with the U.S. Department of Veterans Affairs for EsoGuard. In Q3 2025, the stock saw a significant jump of almost 40% following a multi-jurisdictional CAC meeting, but subsequently dropped after a stock sale announcement. Lucid Diagnostics closed a public offering of 28,750,000 shares of common stock at $1.00 per share, raising approximately $27.0 million in net proceeds. The company entered into an ATM offering facility for up to $25.0 million of common stock, with 4,161,747 shares sold as of March 23, 2026, generating approximately $5.3 million in net proceeds.

While there is information regarding the seasonality of Lucid Diagnostics' stock performance, the available information suggests a generally increasing demand for its products and services rather than distinct demand seasonality. The company has reported continued growing demand for EsoGuard esophageal precancer testing and strong underlying demand for its products, with test volumes increasing sequentially and annually. The company's focus on expanding access through initiatives like the VA contract and engagement with health systems aims to further drive this demand.

Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company focused on the early detection of esophageal precancer and cancer. Its core business revolves around the EsoGuard Esophageal DNA Test and the EsoCheck Esophageal Cell Collection Device. The EsoGuard test is a non-invasive molecular diagnostic test designed to detect esophageal precancer and cancer by analyzing DNA methylation markers. The company also operates LucidDx Labs Inc., a CLIA-certified, CAP-accredited clinical laboratory that processes EsoGuard tests. Lucid Diagnostics aims to prevent deaths from esophageal adenocarcinoma through early detection in at-risk patients with gastroesophageal reflux disease (GERD).

Lucid Diagnostics Inc. is headquartered in New York, New York, United States, and was incorporated in 2018. The company primarily operates in the United States, where its CLIA-certified, CAP-accredited laboratory, LucidDx Labs, is also located.

Lucid Diagnostics has maintained a positive brand reputation, driven by strong clinical evidence and strategic partnerships. Positive real-world data from nearly 12,000 patients confirmed excellent technical performance and rapid cell collection times. The U.S. Department of Veterans Affairs contract expanded access and validated the utility of their diagnostic tools. The company is nearing a critical Medicare coverage milestone for EsoGuard, which could significantly transform its business model. Highmark Blue Cross Blue Shield issued a positive coverage policy for EsoGuard in New York State.

Individual investors collectively hold the largest stake in Lucid Diagnostics, with 40% of the shares. PAVmed Inc. is the largest single shareholder, owning approximately 27.5% as of December 31, 2025, and 21% as of March 23, 2026. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., Masters Capital Management Llc, Standard Life Aberdeen plc, Two Seas Capital LP, Geode Capital Management, Llc, State Street Corp, Perkins Capital Management Inc, Wells Fargo & Company/mn, and Renaissance Technologies Llc. The CEO, Lishan Aklog, holds 1.1% of the company's shares.